A federal judge has reduced a $9 billion punitive damages verdict against the manufacturers of Type 2 diabetes drug Actos to less than $37 million.
U.S. District Judge Rebecca Doherty of the Western District of Louisiana on Monday denied a motion by the defendants for new trial in the first federal bellwether test of claims that taking Actos increased the risk of getting bladder cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
